Articles

Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations

Alzheimer’s disease (AD) is a progressive and irreversible brain disorder. Hippocampus is one of the involved regions and its atrophy is a widely used biomarker for AD diagnosis. We have recently developed Den...

Authors: Sreevani Katabathula, Qinyong Wang and Rong Xu

Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model

Old age, the most important risk factor for Alzheimer’s disease (AD), is associated with thermoregulatory deficits. Brown adipose tissue (BAT) is the main thermogenic driver in mammals and its stimulation, thr...

Authors: Marine Tournissac, Tra-My Vu, Nika Vrabic, Clara Hozer, Cyntia Tremblay, Koralie Mélançon, Emmanuel Planel, Fabien Pifferi and Frédéric Calon

Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease

Authors: Laura E. Donovan, Eric B. Dammer, Duc M. Duong, John J. Hanfelt, Allan I. Levey, Nicholas T. Seyfried and James J. Lah

A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study

Neurofilament light in serum (sNfL) is a biomarker for axonal damage with elevated levels in many neurological disorders, including neurodegenerative dementias. Since within-group variation of sNfL is large an...

Authors: E. A. J. Willemse, P. Scheltens, C. E. Teunissen and E. G. B. Vijverberg

Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology

Little is known about the heterogeneous etiology of suspected non-Alzheimer’s pathophysiology (SNAP), a group of subjects with neurodegeneration in the absence of β-amyloid. Using antemortem MRI and pathologic...

Authors: L. E. M. Wisse, R. de Flores, L. Xie, S. R. Das, C. T. McMillan, J. Q. Trojanowski, M. Grossman, E. B. Lee, D. Irwin, P. A. Yushkevich and D. A. Wolk

Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) radiotracer in positron emission tomography (P...

Authors: Sarah K. Royse, Davneet S. Minhas, Brian J. Lopresti, Alice Murphy, Tyler Ward, Robert A. Koeppe, Santiago Bullich, Susan DeSanti, William J. Jagust and Susan M. Landau

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Authors: Jeffrey Cummings, Paul Aisen, Cynthia Lemere, Alireza Atri, Marwan Sabbagh and Stephen Salloway

Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets

The Placebo Group Simulation Approach (PGSA) aims at partially replacing randomized placebo-controlled trials (RPCTs), making use of data from historical control groups in order to decrease the needed number o...

Authors: Manfred Berres, Andreas U. Monsch and René Spiegel

Anticancer drugs repurposed for Alzheimer’s disease: a systematic review

The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alz...

Authors: Antonio Ancidoni, Ilaria Bacigalupo, Giulia Remoli, Eleonora Lacorte, Paola Piscopo, Giulia Sarti, Massimo Corbo, Nicola Vanacore and Marco Canevelli

The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker stat...

Authors: Maitee Rosende-Roca, Carla Abdelnour, Ester Esteban, Juan Pablo Tartari, Emilio Alarcon, Juliana Martínez-Atienza, Antonio González-Pérez, María E. Sáez, Asunción Lafuente, Mar Buendía, Ana Pancho, Nuria Aguilera, Marta Ibarria, Susana Diego, Sara Jofresa, Isabel Hernández…

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as ...

Authors: Freyja Aichholzer, Hans-Wolfgang Klafki, Isabella Ogorek, Jonathan Vogelgsang, Jens Wiltfang, Norbert Scherbaum, Sascha Weggen and Oliver Wirths

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET

We aimed to investigate the tau biomarker discrepancies of Alzheimer’s disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal fluid (CSF) p-tau181, and AV1451 positron emission...

Authors: Yu Guo, Yu-Yuan Huang, Xue-Ning Shen, Shi-Dong Chen, Hao Hu, Zuo-Teng Wang, Lan Tan and Jin-Tai Yu

Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease

Identifying novel therapeutic targets is crucial for the successful development of drugs. However, the cost to experimentally identify therapeutic targets is huge and only approximately 400 genes are targets f...

Authors: Shingo Tsuji, Takeshi Hase, Ayako Yachie-Kinoshita, Taiko Nishino, Samik Ghosh, Masataka Kikuchi, Kazuro Shimokawa, Hiroyuki Aburatani, Hiroaki Kitano and Hiroshi Tanaka

Investigating the relationship between BMI across adulthood and late life brain pathologies

In view of reported associations between high adiposity, particularly in midlife and late-life dementia risk, we aimed to determine associations between body mass index (BMI), and BMI changes across adulthood ...

Authors: Christopher A. Lane, Josephine Barnes, Jennifer M. Nicholas, John W. Baker, Carole H. Sudre, David M. Cash, Thomas D. Parker, Ian B. Malone, Kirsty Lu, Sarah-Naomi James, Ashvini Keshavan, Sarah Buchanan, Sarah Keuss, Heidi Murray-Smith, Andrew Wong, Elizabeth Gordon…

Characterization of the initial complaint and care pathways prior to diagnosis in very young sporadic Alzheimer’s disease

Very-early-onset Alzheimer’s disease (young-AD) differentiates from late-onset AD (old-AD) by a predominant involvement of the parietal neocortex leading to atypical presentations. The diagnosis of AD is often...

Authors: Pauline Olivieri, Lorraine Hamelin, Julien Lagarde, Valérie Hahn, Elodie Guichart-Gomez, Carole Roué-Jagot and Marie Sarazin

Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study

Functional decline in Alzheimer’s disease (AD) is typically measured using single-time point subjective rating scales, which rely on direct observation or (caregiver) recall. Remote monitoring technologies (RM...

Authors: Marijn Muurling, Casper de Boer, Rouba Kozak, Dorota Religa, Ivan Koychev, Herman Verheij, Vera J. M. Nies, Alexander Duyndam, Meemansa Sood, Holger Fröhlich, Kristin Hannesdottir, Gul Erdemli, Federica Lucivero, Claire Lancaster, Chris Hinds, Thanos G. Stravopoulos…

Correction to: The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice

An amendment to this paper has been published and can be accessed via the original article.

Authors: Jing Di, Ibrar Siddique, Zizheng Li, Ghattas Malki, Simon Hornung, Suman Dutta, Ian Hurst, Ella Ishaaya, Austin Wang, Sally Tu, Ani Boghos, Ida Ericsson, Frank-Gerrit Klärner, Thomas Schrader and Gal Bitan

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M₁ receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

The cholinergic system and M₁ receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M₁ receptor partial agonist HTL0018318 is under development for the symptomatic ...

Authors: Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert Jan Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld and Pradeep J. Nathan

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease

Blood neurofilament light (Nfl) and total-tau (t-tau) have been described to be increased in several neurological conditions, including prion diseases and other neurodegenerative dementias. Here, we aim to det...

Authors: Inga Zerr, Anna Villar-Piqué, Peter Hermann, Matthias Schmitz, Daniela Varges, Isidre Ferrer, Joachim Riggert, Henrik Zetterberg, Kaj Blennow and Franc Llorens

Use of the Clock Drawing Test and the Rey–Osterrieth Complex Figure Test-copy with convolutional neural networks to predict cognitive impairment

The Clock Drawing Test (CDT) and Rey–Osterrieth Complex Figure Test (RCFT) are widely used as a part of neuropsychological test batteries to assess cognitive function. Our objective was to confirm the predicti...

Authors: Young Chul Youn, Jung-Min Pyun, Nayoung Ryu, Min Jae Baek, Jae-Won Jang, Young Ho Park, Suk-Won Ahn, Hae-Won Shin, Kwang-Yeol Park and Sang Yun Kim

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease

The primary study objective of this retrospective academic memory clinic-based observational longitudinal study was to investigate the prognostic value of a cerebrospinal fluid (CSF)-based ATN classification f...

Authors: Koen Delmotte, Jolien Schaeverbeke, Koen Poesen and Rik Vandenberghe

Correction to: Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation

An amendment to this paper has been published and can be accessed via the original article.

Authors: Woo Shik Shin, Jing Di, Qin Cao, Binsen Li, Paul M. Seidler, Kevin A. Murray, Gal Bitan and Lin Jiang

Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging

Detecting subtle-to-moderate biomarker changes such as those in amyloid PET imaging becomes increasingly relevant in the context of primary and secondary prevention of Alzheimer’s disease (AD). This work aimed...

Authors: Isadora Lopes Alves, Fiona Heeman, Lyduine E. Collij, Gemma Salvadó, Nelleke Tolboom, Natàlia Vilor-Tejedor, Pawel Markiewicz, Maqsood Yaqub, David Cash, Elizabeth C. Mormino, Philip S. Insel, Ronald Boellaard, Bart N. M. van Berckel, Adriaan A. Lammertsma, Frederik Barkhof and Juan Domingo Gispert

Associations of healthy lifestyles with cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact older adults: the CABLE study

We aimed to investigate the associations between healthy lifestyles and Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF).

Authors: Xiao-He Hou, Wei Xu, Yan-Lin Bi, Xue-Ning Shen, Ya-Hui Ma, Qiang Dong, Lan Tan and Jin-Tai Yu

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomize...

Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings

Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profil...

Authors: James D. Doecke, Cindy Francois, Christopher J. Fowler, Erik Stoops, Pierrick Bourgeat, Stephanie R. Rainey-Smith, Qiao-Xin Li, Colin L. Masters, Ralph N. Martins, Victor L. Villemagne, Steven J. Collins and Hugo Marcel Vanderstichele

Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia

Pain is common among individuals with Alzheimer’s disease and related dementias (ADRD), and use of opioids has been increasing over the last decade. Yet, it is unclear to what extent opioids are appropriately ...

Authors: Yu-Jung Jenny Wei, Siegfried Schmidt, Cheng Chen, Roger B. Fillingim, M. Carrington Reid, Steven DeKosky, Laurence Solberg, Marco Pahor, Babette Brumback and Almut G. Winterstein

COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients

There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19).

Authors: Agathe Vrillon, Elsa Mhanna, Clément Aveneau, Manon Lebozec, Lina Grosset, Diane Nankam, Fernanda Albuquerque, Raphaelle Razou Feroldi, Barbara Maakaroun, Iana Pissareva, Dalenda Cherni Gherissi, Julien Azuar, Véronique François, Claire Hourrègue, Julien Dumurgier, Lisette Volpe-Gillot…

A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease

Aducanumab is an anti-amyloid-β (Aβ) antibody that achieved reduced amyloid pathology in Alzheimer’s disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggest...

Authors: Gerhard Leinenga, Wee Kiat Koh and Jürgen Götz

Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults

We examined in cognitively intact older adults the relative weight of cognitive, genetic, structural and amyloid brain imaging variables for predicting cognitive change over a 4-year time course.

Authors: Jolien M. Schaeverbeke, Silvy Gabel, Karen Meersmans, Emma S. Luckett, Steffi De Meyer, Katarzyna Adamczuk, Natalie Nelissen, Valerie Goovaerts, Ahmed Radwan, Stefan Sunaert, Patrick Dupont, Koen Van Laere and Rik Vandenberghe

Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population

Subjective cognitive decline (SCD) represents a cognitively normal state but at an increased risk for developing Alzheimer’s disease (AD). Recognizing the glucose metabolic biomarkers of SCD could facilitate t...

Authors: Qiu-Yue Dong, Tao-Ran Li, Xue-Yan Jiang, Xiao-Ni Wang, Ying Han and Jie-Hui Jiang

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice

Major depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimer’s disease (AD). Despite both diseases having a robust genetic component, t...

Authors: Ana Martín-Sánchez, Janet Piñero, Lara Nonell, Magdalena Arnal, Elena M. Ribe, Alejo Nevado-Holgado, Simon Lovestone, Ferran Sanz, Laura I. Furlong and Olga Valverde

A novel age-informed approach for genetic association analysis in Alzheimer’s disease

Many Alzheimer’s disease (AD) genetic association studies disregard age or incorrectly account for it, hampering variant discovery.

Authors: Yann Le Guen, Michael E. Belloy, Valerio Napolioni, Sarah J. Eger, Gabriel Kennedy, Ran Tao, Zihuai He and Michael D. Greicius

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease

Multiple pathophysiological processes have been described in Alzheimer’s disease (AD). Their inter-individual variations, complex interrelations, and relevance for clinical manifestation and disease progressio...

Authors: Christopher Clark, Loïc Dayon, Mojgan Masoodi, Gene L. Bowman and Julius Popp

The efficacy of exergaming in people with major neurocognitive disorder residing in long-term care facilities: a pilot randomized controlled trial

It is currently unknown whether exergaming is efficacious in people with major neurocognitive disorder (MNCD) residing in long-term care facilities. This pilot randomized controlled trial (RCT) explored the ef...

Authors: Nathalie Swinnen, Mathieu Vandenbulcke, Eling D. de Bruin, Riekje Akkerman, Brendon Stubbs, Joseph Firth and Davy Vancampfort

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease

To investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer’s disease.

Authors: Cécile Tissot, Andréa L. Benedet, Joseph Therriault, Tharick A. Pascoal, Firoza Z. Lussier, Paramita Saha-Chaudhuri, Mira Chamoun, Melissa Savard, Sulantha S. Mathotaarachchi, Gleb Bezgin, Yi-Ting Wang, Jaime Fernandez Arias, Juan Lantero Rodriguez, Anniina Snellman, Nicholas J. Ashton, Thomas K. Karikari…

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer’s disease (AD) pathology in the form of AD-relate...

Authors: Claudia Cicognola, Shorena Janelidze, Joakim Hertze, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren and Oskar Hansson

Early detection of amyloid load using ¹⁸F-florbetaben PET

A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the popul...

Authors: Santiago Bullich, Núria Roé-Vellvé, Marta Marquié, Susan M. Landau, Henryk Barthel, Victor L. Villemagne, Ángela Sanabria, Juan Pablo Tartari, Oscar Sotolongo-Grau, Vincent Doré, Norman Koglin, Andre Müller, Audrey Perrotin, Aleksandar Jovalekic, Susan De Santi, Lluís Tárraga…

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with...

Authors: Seong-Ho Koh, Hyuk Sung Kwon, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park, Hyun Jeong Han, Byeong C. Kim, Jin Se Park, Jee-Young Lee, Sangjae Kim and Kyu-Yong Lee

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression

To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer’s disease (AD) pathology and predict clinical progression in a memory clin...

Authors: Christopher Clark, Piotr Lewczuk, Johannes Kornhuber, Jonas Richiardi, Bénédicte Maréchal, Thomas K. Karikari, Kaj Blennow, Henrik Zetterberg and Julius Popp

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial

To explore the utility of the International Working Group (IWG)-1 criteria in recruitment for Alzheimer’s disease (AD) clinical trials, we applied the more recently proposed research diagnostic criteria to ind...

Authors: Anna Rosenberg, Alina Solomon, Hilkka Soininen, Pieter Jelle Visser, Kaj Blennow, Tobias Hartmann and Miia Kivipelto

A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimer’s disease

Missing data can complicate the interpretability of a clinical trial, especially if the proportion is substantial and if there are different, potentially outcome-dependent causes.

Authors: Floor M. van Oudenhoven, Sophie H. N. Swinkels, Hilkka Soininen, Miia Kivipelto, Tobias Hartmann and Dimitris Rizopoulos

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide with a novel proposed mechanism of action. The first phase 3 clinical trial of G...

Authors: Shifu Xiao, Piu Chan, Tao Wang, Zhen Hong, Shuzhen Wang, Weihong Kuang, Jincai He, Xiaoping Pan, Yuying Zhou, Yong Ji, Luning Wang, Yan Cheng, Ying Peng, Qinyong Ye, Xiaoping Wang, Yuncheng Wu…

Additive interaction of mid- to late-life depression and cerebrovascular disease on the risk of dementia: a nationwide population-based cohort study

Dementia is a progressive neurocognitive disease with a substantial social burden. No apparent breakthroughs in treatment options have emerged so far; thus, disease prevention is essential for at-risk populati...

Authors: Yoo Jin Jang, Cinoo Kang, Woojae Myung, Shinn-Won Lim, Young Kyung Moon, Ho Kim and Doh Kwan Kim

Enhancing magnetic resonance imaging-driven Alzheimer’s disease classification performance using generative adversarial learning

Generative adversarial networks (GAN) can produce images of improved quality but their ability to augment image-based classification is not fully explored. We evaluated if a modified GAN can learn from magneti...

Authors: Xiao Zhou, Shangran Qiu, Prajakta S. Joshi, Chonghua Xue, Ronald J. Killiany, Asim Z. Mian, Sang P. Chin, Rhoda Au and Vijaya B. Kolachalama

Normal levels of KIF5 but reduced KLC1 levels in both Alzheimer disease and Alzheimer disease in Down syndrome: evidence suggesting defects in anterograde transport

Impaired axonal transport may contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) and Down syndrome (DS). Axonal transport is a complex process in which specific mo...

Authors: Xu-Qiao Chen, Utpal Das, Gooho Park and William C. Mobley

Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury

Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide....

Authors: Emily B. Button, Wai Hang Cheng, Carlos Barron, Honor Cheung, Asma Bashir, Jennifer Cooper, Jasmine Gill, Sophie Stukas, David C. Baron, Jerome Robert, Elyn M. Rowe, Peter A. Cripton and Cheryl L. Wellington

Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease

Regenerative therapies to mitigate Alzheimer’s disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells h...

Authors: Lauren A. Apodaca, Al Anoud D. Baddour, Camilo Garcia Jr, Leila Alikhani, Erich Giedzinski, Ning Ru, Anshu Agrawal, Munjal M. Acharya and Janet E. Baulch

27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial

27-Hydroxycholesterol (27-OH), the main circulating oxysterol in humans and the potential missing link between peripheral hypercholesterolemia and Alzheimer’s disease (AD), has not been investigated previously...

Authors: Anna Sandebring-Matton, Julen Goikolea, Ingemar Björkhem, Laura Paternain, Nina Kemppainen, Tiina Laatikainen, Tiia Ngandu, Juha Rinne, Hilkka Soininen, Angel Cedazo-Minguez, Alina Solomon and Miia Kivipelto

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

Single-nucleotide polymorphisms (SNPs) identified by genome-wide association studies only explain part of the heritability of Alzheimer’s disease (AD). Epistasis has been considered as one of the main causes o...

Authors: Hui Wang, David A. Bennett, Philip L. De Jager, Qing-Ye Zhang and Hong-Yu Zhang